Dendreon Opens Cell Processing Center; New Center in Hackensack, NJ Supports Ongoing Phase III Trials for Provenge.Business Editors, Health/Medical Writers SEATTLE--(BW HealthWire)--Nov. 7, 2000 Dendreon Corporation (Nasdaq:DNDN) today announced it has expanded its cell processing capabilities with the opening of a new center in conjunction with Progenitor Cell progenitor cell See stem cell. Therapy, L.L.C., in Hackensack, NJ. At the new center, Progenitor Cell Therapy will prepare Provenge(TM), Dendreon's therapeutic vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. for the treatment of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , and Mylovenge(TM), Dendreon's therapeutic vaccine for multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . The center employs Dendreon's proprietary technology to prepare vaccines utilizing specialized immune cells, called dendritic cells. "This center will provide important support for clinical sites and patients on the East Coast participating in our current Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials of Provenge and our expanding trials of Mylovenge," said Frank Valone, M.D., chief medical officer, Dendreon Corporation. Dendreon's immunotherapy programs are now supported in the U.S. by five cell processing centers. The other centers are located at Dendreon's company headquarters in Seattle, Wash. and satellite office in Mountain View, Calif.; the Mayo Clinic in Rochester, Minn.; and the American Red Cross American Red Cross: see Red Cross. in Philadelphia, Pa. A cell processing center in Tokyo, Japan is operated in conjunction with Kirin Brewery Co., Ltd. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon is focused on the development of therapeutic cancer vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine through the use of antigen discovery, antigen engineering and dendritic cell technologies. Dendreon's vaccine for the treatment of prostate cancer, Provenge(TM), is in Phase III clinical trials and its vaccine for the treatment of multiple myeloma, Mylovenge(TM), is in Phase II clinical trials. Progenitor Cell Therapy, L.L.C. is a commercial cell engineering company that provides for the collection, manufacture, storage and redistribution of human cells for therapeutic purposes through a nationwide network, operated in compliance with current Good Manufacturing Practices. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, risks associated with completing our clinical trials, dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's SEC Reports, including Dendreon's Form 10-Q Form 10-Q See 10-Q. and Form S-1 Registration Statement, No. 333-47706, which are available at www.sec.gov. 3005 First Avenue, Seattle, Washington 98121 206/256-4545 Fax - 206/256-0571 www.dendreon.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion